Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 7Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma 1Stomach Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3cediranib 2temsirolimus 1palbociclib 1montanide ISA 51 1liposomal doxorubicin 1flt3 ligand protein 1entinostat 1Watchful Waiting 1Vorinostat 1Vinorelbine 1Thrombopoietin 1Therapeutics 1Thalidomide 1Stem Cell Factor 1Sirolimus 1SUB1 protein, human 1Radiosurgery 1Psychiatric Rehabilitation 1Propranolol 1Microscopy, Electron 1Mental Status and Dementia Tests 1Interleukin-2 1Immunohistochemistry 1Filgrastim 1Fentanyl 1Docetaxel 1Decitabine 1Cyclophosphamide 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × palbociclib × Dermatologic × Clear all
NCT01037790 2021-03-11

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
304 enrolled 12 charts
BreastDermatologicGastrointestinalGenitourinary

Breast Neoplasms, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Teratoma, Testicular Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡